natgillin/translations-raw huggingface dataset:
In a Phase II study aimed at evaluating Remicade in CHF, higher incidence of mortality due to worsening of heart failure were seen in patients treated with Remicade, especially those treated with the higher dose of 10 mg/kg (i.e. twice the maximum approved dose).
V študiji faze II, katere cilj je bil ovrednotiti zdravilo Remicade pri CHF, so pri bolnikih, zdravljenih s tem zdravilom, ugotavljali večjo incidenco smrtnosti zaradi poslabšanja srčnega popuščanja, še posebej pri tistih, ki so prejemali večji odmerek 10 mg/kg (dvakrat več od največjega odobrenega odmerka).
In Crohn's disease patients who received maintenance treatment, antibodies to infliximab occurred overall in 3.3% of patients receiving immunosuppressants and in 13.3% of patients not receiving immunosuppressants.
Pri bolnikih s Crohnovo boleznijo, ki so prejemali vzdrževalno terapijo, so se protitelesa proti infliksimabu pojavila pri skupno 3,3 % bolnikov, ki so prejemali imunosupresive, in pri 13,3 % tistih, ki niso prejemali imunosupresivov.
Additional histological studies provided evidence that treatment with infliximab reduces the infiltration of inflammatory cells into affected areas of the intestine and the presence of inflammation markers at these sites.
Dodatne histološke študije so pokazale, da zdravljenje z infliksimabom zmanjša potovanje vnetnih celic v prizadete predele črevesja in prisotnost pokazateljev vnetja na teh mestih.
Data to support dose titration in rheumatoid arthritis come from ATTRACT, ASPIRE and the START study.
Podatki, ki govorijo v prid titraciji odmerka pri revmatoidnem artritisu, so bili zbrani v študijah ATTRACT, ASPIRE in START.
Number of patients evaluated for ALT.
Število bolnikov, pri katerih so ovrednotili vrednost ALT.
• Maintenance: Additional infusions of 5 mg/kg every 8 weeks or
• Vzdrževanje: Dodatne infuzije v odmerku 5 mg/kg na vsakih 8 tednov, ali
In a clinical study of patients with Crohn's disease (SONIC), infusion-related reactions occurred in 16.6% (27/163) of patients receiving infliximab monotherapy, 5% (9/179) of patients receiving infliximab in combination with AZA, and 5.6% (9/161) of patients receiving AZA monotherapy.
V klinični študiji pri bolnikih s Crohnovo boleznijo (SONIC) so se z infuzijo povezane reakcije pojavile pri 16,6 % (27/163) bolnikov, ki so prejemali infliksimab v monoterapiji, pri 5 % (9/179) bolnikov, ki so prejemali infliksimab v kombinaciji z AZA, in pri 5,6 % (9/161) bolnikov, ki so prejemali AZA v monoterapiji.
The safety and efficacy of re-administration after a Remicade-free interval of more than 16 weeks has not been established.
Varnosti in učinkovitosti ponovnega dajanja zdravila Remicade po premoru brez zdravila, daljšem od 16 tednov, še niso ugotovili.
Juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis The safety and efficacy of Remicade in children and adolescents younger than 18 years for the indications of juvenile idiopathic arthritis, psoriatic arthritis and ankylosing spondylitis have not been established.
Juvenilni idiopatski artritis, psoriatični artritis in ankilozirajoči spondilitis Varnost in učinkovitost zdravila Remicade pri otrocih in mladostnikih, mlajših od 18 let, za indikacije juvenilni idiopatski artritis, psoriatični artritis in ankilozirajoči spondilitis nista bili dokazani.
Patients who develop a new infection while undergoing treatment with Remicade, should be monitored closely and undergo a complete diagnostic evaluation.
Tiste bolnike, pri katerih se med zdravljenjem z zdravilom Remicade pojavi nova okužba, je treba natančno spremljati in pri njih opraviti celotni diagnostični postopek.
If you have Crohn's disease you will first be given other medicines.
Če imate Crohnovo bolezen, boste najprej prejeli druga zdravila.
Analysis of lamina propria mononuclear cells obtained by biopsy of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells capable of expressing TNF and interferon.
Analiza mononuklearnih celic iz lamine proprie, dobljenih z biopsijo črevesne sluznice, je pokazala, da zdravljenje z infliksimabom povzroči zmanjšanje števila celic, ki lahko tvorijo TNF in interferon .
• That treatment with Remicade may increase the risks of serious infections/sepsis, opportunistic infections, tuberculosis, hepatitis B reactivation, and BCG breakthrough in infants with in utero exposure to infliximab, and when to seek attention from a HCP
• Da lahko zdravljenje z zdravilom Remicade zveča tveganje za resne okužbe/sepso, oportunistične okužbe, tuberkulozo, reaktivacijo hepatitisa B in okužbo z BCG pri dojenčkih, ki so bili in utero izpostavljeni infliksimabu, in kdaj poiskati zdravniško pomoč.
Immunogenicity Antibodies to infliximab were detected in 3 (2.9%) paediatric patients.
Imunogenost Protitelesa na infliksimab so ugotovili pri 3 pediatričnih bolnikih (2,9 %).
Your doctor may recommend temporarily stopping Remicade.
Zdravnik bo morda priporočil začasno prekinitev zdravljenja z zdravilom Remicade.
Patients did not receive any concomitant immunosuppressant therapy.
Ti bolniki niso sočasno prejemali nobenih drugih imunosupresivnih zdravil.
Infections occurred in 68% (41/60) of children receiving 3 mg/kg over 52 weeks, 65% (37/57) of children receiving infliximab 6 mg/kg over 38 weeks and 47% (28/60) of children receiving placebo over 14 weeks (see section 4.4).
Okužbe so se pojavile pri 68 % (41/60) otrok, ki so prejemali infliksimab v odmerku 3 mg/kg v času 52 tednov, pri 65 % (37/57) otrok, ki so prejemali infliksimab v odmerku 6 mg/kg v času 38 tednov, in pri 47 % (28/60) otrok, ki so prejemali placebo v času 14 tednov (glejte poglavje 4.4).
• Store in a refrigerator (2 °C - 8 °C).
• Shranjujte v hladilniku (2 °C - 8 °C).
If latent tuberculosis is suspected, a physician with expertise in the treatment of tuberculosis should be consulted.
Pri sumu na latentno tuberkulozo se posvetujte z zdravnikom, izkušenim v zdravljenju tuberkuloze.
There was one reported malignancy amongst 77 control patients (median duration of follow-up 0.8 years; incidence 1.3% [95% CI 0.03%-7.0%]).
Pri 77 bolnikih iz kontrolne skupine so poročali o enem malignomu (mediana dolžine spremljanja bolnikov je bila 0,8 let, incidenca pa 1,3 % [95 % IZ 0,03 %-7,0 %]).
• Bacterial infections such as blood poisoning, abscess or infection of the skin (cellulitis)
• bakterijske okužbe, na primer zastrupitev krvi, absces ali okužba kože (celulitis)
In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalisation of keratinocyte differentiation in psoriatic plaques.
Pri bolnikih s psoriazo je zdravljenje z infliksimabom povzročilo zmanjšanje vnetja v epidermisu in normalizacijo diferenciacije keratinocitov v psoriatičnih žariščih.
In patients treated with methotrexate alone, the incidence of serious infections was 5.2% in patients 65 years and older compared to 2.7% in patients under 65 (see section 4.4).
Pri bolnikih, zdravljenih samo z metotreksatom in starih 65 let ali več, je bila incidenca resnih okužb 5,2 % v primerjavi z 2,7 % pri mlajših od 65 let (glejte poglavje 4.4).
For more information about the safety of Remicade in elderly patients (see sections 4.4 and 4.8).
Za več informacij o varnosti zdravila Remicade pri starejših glejte poglavji 4.4 in 4.8.
However, if the solution is prepared in germ-free conditions, it can be stored in a refrigerator at 2 °C to 8 °C up to 28 days and for an additional 24 hours at 25 °C after removal from the refrigerator.
Vendar, če je bila raztopina pripravljena v aseptičnih pogojih, jo lahko do 28 dni shranjujete v hladilniku pri temperaturi 2 °C do 8 °C ter dodatnih 24 ur pri temperaturi 25 °C, po tem ko jo vzamete iz hladilnika.
There are insufficient data on the incidence of delayed hypersensitivity reactions after Remicade-free intervals of more than 1 year but limited data from clinical studies suggest an increased risk for delayed hypersensitivity with increasing Remicade-free interval (see section 4.4).
Podatki o incidenci poznih preobčutljivostnih reakcij po premoru brez zdravila Remicade, daljšem od enega leta, so nezadostni, vendar omejeni podatki iz kliničnih preskušanj kažejo povečano tveganje za pozno preobčutljivost pri povečevanju premora brez zdravila Remicade (glejte poglavje 4.4).
EXPRESS Placebo → Infliximab 5 mg/kg (at week 24)
EXPRESS placebo → infliximab 5 mg/kg (24 teden)
In most fistulising Crohn's disease patients, infliximab was detected in serum for 12 weeks (range 4-28 weeks) after administration of the regimen.
Pri večini bolnikov s Crohnovo boleznijo s fistulami so infliksimab ugotavljali v serumu še 12 tednov (razpon: od 4 do 28 tednov) po infuziji.
The combination of Remicade with other biological therapeutics used to treat the same conditions as Remicade, including anakinra and abatacept, is not recommended (see section 4.4).
Kombiniranje zdravila Remicade z drugimi biološkimi zdravili za zdravljenje enakih bolezni kot z zdravilom Remicade, vključno z anakinro in abataceptom, ni priporočljivo (glejte poglavje 4.4).
PGA of cleared (0) or minimal (1)
PGA brez plakov (0) ali minimalni (1)
Limited experience from re-treatment with one single Remicade dose in psoriasis after an interval of 20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions when compared to the initial induction regimen (see section 5.1).
Omejene izkušnje s ponovnim zdravljenjem z enim samim odmerkom zdravila Remicade pri psoriazi po časovnem presledku 20 tednov kažejo zmanjšano učinkovitost in večjo incidenco blagih do zmernih z infuzijo povezanih reakcij v primerjavi s prvotnim uvodnim režimom zdravljenja (glejte poglavje 5.1).
> 40 weeks
> 40 tednov
(DMARDs), including methotrexate, has been inadequate.
(DMARD - disease modifying antirheumatic drugs), ki vplivajo na imunsko odzivnost, vključno z metotreksatom, ni zadosten.
Elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving Remicade than in controls, both when Remicade was given as monotherapy and when it was used in combination with other immunosuppressive agents.
Zvišanje aminotransferaz (ALT pogosteje kot AST) so opažali pri večjem deležu bolnikov, ki so prejemali zdravilo Remicade, kot v kontrolni skupini, in sicer tako med dajanjem zdravila Remicade v monoterapiji kot pri njegovi uporabi v kombinaciji z drugimi imunosupresivnimi sredstvi.
> 54 weeks
> 54 tednov
It is not known whether this finding was due to effects on the males and/or the females.
Ni znano, ali je to posledica učinka zdravila na samce, na samice ali na oba spola.
All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias (e.g. persistent fever, bruising, bleeding, pallor).
Vsem bolnikom svetujte, naj takoj poiščejo zdravniško pomoč, če se jim pojavijo znaki in simptomi, ki kažejo na krvno diskrazijo (npr. trdovratna zvišana telesna temperatura, podplutbe, krvavitve in bledica).
Available data suggest an increased risk for delayed hypersensitivity with increasing Remicade-free interval.
Podatki, ki so na voljo, kažejo povečano tveganje za pozno preobčutljivost pri povečevanju premora brez prejemanja zdravila Remicade.
• Tell your doctor before you are given Remicade if you have or have ever had lymphoma (a type of blood cancer) or any other cancer.
• Preden prejmete zdravilo Remicade, povejte zdravniku, če imate ali ste imeli kdaj v preteklosti limfom (vrsta krvnega raka) oziroma katero koli drugo vrsto raka.
Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of infliximab, revealed a substantial reduction in detectable TNF.
Histološka preiskava biopsijskih vzorcev kolona, odvzetih pred uporabo infliksimaba in 4 tedne po njej, je pokazala znatno zmanjšanje merljivega TNF.
• If you received Remicade during your pregnancy, your baby may have a higher risk for getting an infection.
• Če ste v času nosečnosti prejemali zdravilo Remicade, ima vaš dojenček lahko povečano tveganje za okužbe.
In psoriatic arthritis patients who received 5 mg/kg with and without methotrexate, antibodies occurred overall in 15% of patients (antibodies occurred in 4% of patients receiving methotrexate and in 26% of patients not receiving methotrexate at baseline).
Pri bolnikih s psoriatičnim artritisom, ki so prejemali odmerek 5 mg/kg z ali brez metotreksata, so našli protitelesa pri skupaj 15 % bolnikov (protitelesa so se pojavila pri 4 % bolnikov, ki so prejemali metotreksat in pri 26 % bolnikov, ki niso prejemali metotreksata na začetku študije).
In case maintenance therapy is interrupted, and there is a need to restart treatment, use of a re-induction regimen is not recommended (see section 4.8).
V primeru prekinitve vzdrževalnega zdravljenja in potrebe po ponovni uvedbi zdravljenja ni priporočljiva ponovna uporaba uvodne sheme (glejte poglavje 4.8).
Before starting treatment with Remicade, all patients must be evaluated for both active and inactive (‘latent') tuberculosis.
Pred začetkom zdravljenja z zdravilom Remicade, morate vse bolnike pregledati in preiskati, da ugotovite morebitno aktivno ali neaktivno (latentno) tuberkulozo.
During clinical studies of Remicade across all approved indications the incidence of lymphoma in Remicade-treated patients was higher than expected in the general population, but the occurrence of lymphoma was rare.
Med kliničnimi preskušanji zdravila Remicade za vse odobrene indikacije je bila pri bolnikih, zdravljenih z zdravilom Remicade, incidenca limfoma višja od pričakovane za splošno populacijo, vendar se je limfom dejansko pojavljal redko.
In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab (see section 4.4: “Infusion reactions and hypersensitivity”).
Pri bolnikih, ki so jim psoriazo vzdrževalno zdravili z infliksimabom brez spremljajočega imunomodulatorja, so se pri približno 28 % razvila protitelesa proti infliksimabu (glejte poglavje 4.4: ''Z infuzijo povezane reakcije in preobčutljivost'').
Patients who have inflammatory diseases already take medicines to treat their problem.
Bolniki z vnetnimi boleznimi že prejemajo zdravila za zdravljenje le teh.
• or alone in patients who show intolerance to methotrexate or for whom methotrexate is contraindicated
• ali samostojno pri bolnikih, ki ne prenašajo metotreksata ali pri katerih je metotreksat kontraindiciran.
In clinical studies, infections have been reported in a higher proportion of paediatric patients compared to adult patients (see section 4.8).
V kliničnih študijah so o okužbah poročali pogosteje pri pediatričnih bolnikih kot pri odraslih bolnikih (glejte poglavje 4.8).
Remicade works by selectively attaching to TNF alpha and blocking its action.
Zdravilo Remicade deluje tako, da se selektivno veže na TNF-alfa in zavira njegovo delovanje.
Table 5 Effects on response and remission rate, data from ACCENT I (week-2 responders) ACCENT I (week-2 responders) % of Patients
Preglednica 5 Učinki na stopnjo odziva in ponovitev bolezni pri bolnikih; podatki iz študije ACCENT I (bolniki z odzivom v 2. tednu) ACCENT I (bolniki z odzivom v 2. tednu) % bolnikov
Indication Number of patients
Število bolnikov
optic neuritis and Guillain-Barré syndrome
vnetje vidnega živca in Guillain-Barréjev sindrom
Patients may be pre-treated with e.g., an antihistamine, hydrocortisone and/or paracetamol and infusion rate may be slowed in order to decrease the risk of infusion-related reactions especially if infusion-related reactions have occurred previously (see section 4.4).
Za zmanjšanje tveganja za pojav z infuzijo povezanih reakcij lahko bolnikom že prej date npr. antihistaminik, hidrokortizon in/ali paracetamol in upočasnite hitrost infundiranja, še posebej če so se z infuzijo povezane reakcije pojavile že kdaj prej (glejte poglavje 4.4).
There were no serious infusion reactions, and 2 subjects in REACH had non-serious anaphylactic reactions.
Ni bilo nobene resne z infuzijo povezane reakcije, dva preiskovanca v preskušanju REACH pa sta imela anafilaktično reakcijo, ki ni bila resna.
Studies have not been performed in patients with liver or renal disease.
Tudi študij pri bolnikih z jetrno ali ledvično boleznijo ni bilo.
In clinical studies, delayed hypersensitivity reactions have been reported.
V kliničnih preskušanjih so poročali o poznih preobčutljivostnih reakcijah.
Chemical and physical in use stability of the diluted solution has been demonstrated for up to 28 days at 2 °C to 8 °C and for an additional 24 hours at 25 °C after removal from refrigeration.
Dokazano je bilo, da je razredčena raztopina zdravila Remicade kemično in fizikalno stabilna do 28 dni pri temperaturi 2 °C do 8 °C ter dodatnih 24 ur pri temperaturi 25 °C, po tem ko se vzame iz hladilnika.
Type 1 glass vial with rubber stopper and aluminium crimp protected by a plastic cap.
Viala (steklo tipa 1) z gumijastim zamaškom in aluminijasto zaporko, zaščiteno s plastično ploščico.
Calculate the total volume of reconstituted Remicade solution required.
Izračunajte celoten volumen potrebne rekonstituirane raztopine zdravila Remicade.
Elevations of ALT ≥ 5 x Upper Limit of Normal (ULN) have been observed (see Table 2).
Opazili so zvišanje vrednosti ALT na ≥ 5-kratnik zgornje meje normalnih vrednosti (glejte preglednico 2).
At baseline 53% of patients were receiving immunomodulator therapy (6-MP, AZA and/or MTX) and 62% of patients were receiving corticosteroids.
Na začetku študije je 53 % bolnikov prejemalo imunomodulatorje (6-MP, AZA in/ali MTX), 62 % bolnikov pa je prejemalo kortikosteroide.
Psoriatic arthritis, ankylosing spondylitis (Bechterew's disease), psoriasis, ulcerative colitis and Crohn's disease
Psoriatični artritis, ankilozirajoči spondilitis (Bechterew sindrom), psoriaza, ulcerozni kolitis in Crohnova bolezen
Remicade is produced in packs of 1, 2, 3, 4 or 5 vials.
Zdravilo Remicade je pakirano po 1, 2, 3, 4 ali 5 vial.
Corticosteroid taper was permitted after week 8.
Zmanjševanje odmerka kortikosteroidov je bilo dovoljeno po 8. tednu.
• Fast heart beat (tachycardia) or palpitations
• hitro bitje srca (tahikardija) ali razbijanje (palpitacije)
Particular attention regarding the risk for infection should be paid when treating the elderly (see section 4.8).
Pri zdravljenju starejših je torej treba posvetiti posebno pozornost tveganju za nastanek okužbe (glejte poglavje 4.8).
Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.
Ni videti, da bi imeli kortikosteroidi klinično pomemben vpliv na farmakokinetiko infliksimaba.
Patients were followed up to 26 weeks.
Spremljali so jih do 26 tednov.
Table 10 Summary of PASI response, PGA response and percent of patients with all nails cleared at weeks 10, 24 and 50.
Preglednica 10 Povzetek odzivov PASI,vrednosti PGA in delež bolnikov z nohti brez psoriatičnih sprememb v 10, 24 in 50 tednu.
At week 2, all patients were assessed for clinical response and randomised to one of 3 treatment groups; a placebo maintenance group, 5 mg/kg maintenance group and 10 mg/kg maintenance group.
V drugem tednu zdravljenja so pri vseh bolnikih ocenili klinični odziv in jih naključno razvrstili v eno od 3 terapevtskih skupin: skupino za vzdrževalno zdravljenje s placebom, skupino za vzdrževalno zdravljenje z odmerkom 5 mg/kg in skupino za vzdrževalno zdravljenje z odmerkom 10 mg/kg.
The educational programme consists of a patient reminder card to be held by the patient.
Izobraževalni program obsega opozorilno kartico za bolnika, ki jo ima bolnik pri sebi.
Concurrent use of stable doses of conventional therapies was permitted, and 92% of patients continued to receive these therapies.
Sočasno jemanje stalnih odmerkov konvencionalnih zdravil je bilo dovoljeno in 92 % bolnikov je med študijo še naprej prejemalo to terapijo.
Patients who were randomised to the placebo maintenance group and then later crossed over to infliximab are included in the infliximab group in the ALT analysis.
Bolniki, ki so jih naključno razporedili v skupino za vzdrževalno zdravljenje s placebom in so potem prešli v skupino za zdravljenje z infliksimabom, so bili pri analizi ALT vključeni v infliksimabovo skupino.
Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed taking into account both the risk for severe fungal infection and the risks of antifungal therapy.
Med izvajanjem diagnostičnih preiskav je treba razmisliti o ustreznem empiričnem protiglivičnem zdravljenju, upoštevajoč tako tveganje za hudo glivično okužbo kot tudi tveganja samega protiglivičnega zdravljenja.
There are no known side effects of having too much of Remicade.
Ni poznanih neželenih učinkov zaradi prejetja prevelikega odmerka zdravila Remicade.
• Inflamed liver caused by a problem with the immune system (autoimmune hepatitis)
• vneta jetra zaradi težav z imunskim sistemom (avtoimunski hepatitis)
The reduction in incidence of colectomy was also examined in another randomised, double-blind study (C0168Y06) in hospitalised patients (n = 45) with moderately to severely active ulcerative colitis who failed to respond to intravenous corticosteroids and who were therefore at higher risk for colectomy.
Zmanjšanje incidence kolektomij so proučevali še v eni randomizirani, dvojno slepi študiji (C0168Y06) pri hospitaliziranih bolnikih (n = 45) z zmerno do močno aktivnim ulceroznim kolitisom, ki se niso odzvali na zdravljenje z intravenskimi kortikosteroidi in so imeli zato večje tveganje, da bo pri njih potrebna kolektomija.
Immunogenicity Antibodies to infliximab were detected in 4 (7.7%) patients through week 54.
Imunogenost Protitelesa proti infliksimabu so v obdobju do konca 54. tedna ugotovili pri 4 (7,7 %) bolnikih.
19 weeks
19 tednov
Appropriate screening tests (e.g. tuberculin skin test, chest X-ray, and/or Interferon Gamma Release Assay), should be performed in all patients (local recommendations may apply).
Pri vseh bolnikih je treba opraviti ustrezne presejalne teste (npr. tuberkulinski kožni test, rentgensko slikanje prsnega koša in/ali test sproščanja interferona gama) (v skladu z lokalnimi priporočili).
Patients should be advised to seek immediate medical advice if they experience any delayed adverse reaction (see section 4.8).
Bolnikom naročite, naj nemudoma poiščejo zdravniško pomoč, če opazijo katerega od poznih neželenih učinkov (glejte poglavje 4.8).
Administer the infusion solution over a period of not less than the infusion time recommended (see section 4.2).
Infuzijsko raztopino infundirajte bolniku v času, ki naj ne bo krajši od priporočenega trajanja infuzije (glejte poglavje 4.2).
In both studies, physical function and quality of life as measured by the BASFI and the physical component score of the SF-36 were also improved significantly.
V obeh študijah sta se bistveno izboljšala telesno stanje bolnikov in kakovost njihovega življenja merjeno po lestvici BASFI, pa tudi telesna komponenta ocene po SF-36 je bila bistveno izboljšana.
All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before therapy and throughout their disease course.
Pri vseh bolnikih z ulceroznim kolitisom, pri katerih obstaja povečano tveganje za displazijo ali karcinom kolona (na primer pri bolnikih z dolgotrajnim ulceroznim kolitisom ali primarnim sklerozantnim holangitisom) ter pri tistih, ki imajo displazijo ali karcinom kolona v pretekli anamnezi, morate redno opravljati presejalne teste za displazijo, tako pred zdravljenjem kot med samo boleznijo.
• In case you have received Remicade while you were pregnant, it is important that you inform your baby's doctor about it before your baby receives any vaccine.
• Če ste med nosečnostjo prejeli zdravilo Remicade, je pomembno, da o tem obvestite zdravnika vašega dojenčka, preden dojenček prejme katero koli cepivo.